ID

17232

Beskrivning

Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00379119

Länk

https://clinicaltrials.gov/show/NCT00379119

Nyckelord

Versioner (1)
  1. 2016-09-01 2016-09-01 -
Uppladdad den

1 september 2016

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Prostate Cancer NCT00379119

Engelsk

Eligibility Prostate Cancer NCT00379119

1 Formulär  
Criteria
Beskrivning

Criteria

histologically confirmed adenocarcinoma of the prostate
Beskrivning

adenocarcinoma of the prostate

Datatyp

boolean

Alias
UMLS CUI [1]
C0007112
underwent prior radical prostatectomy as local definitive therapy for prostate cancer
Beskrivning

Radical prostatectomy

Datatyp

boolean

Alias
UMLS CUI [1]
C0194810
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery
Beskrivning

androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade)

Datatyp

boolean

Alias
UMLS CUI [1]
C1518041
UMLS CUI [2]
C3495882
serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease
Beskrivning

rising prostate-specific antigen; no objective evidence of metastatic disease

Datatyp

boolean

Alias
UMLS CUI [1]
C0201544
UMLS CUI [2]
C0027627
prior radiotherapy for serologic progression allowed
Beskrivning

Radiotherapy

Datatyp

boolean

Alias
UMLS CUI [1]
C1522449
did not receive any form of androgen blockade therapy within the past 9 months
Beskrivning

androgen blockade therapy

Datatyp

boolean

Alias
UMLS CUI [1]
C0279492
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
Beskrivning

no metastatic disease by abdominal/pelvic ct scan and whole-body scan

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0203669
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C1641132
Inclusion Criteria: Patient Characteristics
Beskrivning

Inclusion Criteria: Patient Characteristics

Alias
UMLS CUI-1
C0815172
able to tolerate ct scanning in the supine position
Beskrivning

CT scan

Datatyp

boolean

Alias
UMLS CUI [1]
C0040405
no prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
Beskrivning

medical condition affecting the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0040113
UMLS CUI [2]
C0026896
UMLS CUI [3]
C0024299
UMLS CUI [4]
C0020550
UMLS CUI [5]
C0006625
no autoimmune disorders
Beskrivning

autoimmune disorders

Datatyp

boolean

Alias
UMLS CUI [1]
C0004364
no acute illness, including active infection requiring antibiotics
Beskrivning

no acute illness, including active infection

Datatyp

boolean

Alias
UMLS CUI [1]
C0001314
UMLS CUI [2]
C0009450
prior concurrent therapy: see disease characteristics
Beskrivning

concurrent therapy

Datatyp

boolean

Alias
UMLS CUI [1]
C0009429
no prior systemic chemotherapy
Beskrivning

systemic chemotherapy

Datatyp

boolean

Alias
UMLS CUI [1]
C1883256
no prior immunological therapy
Beskrivning

immunological therapy

Datatyp

boolean

Alias
UMLS CUI [1]
C0021083
no prior single-agent antiandrogen (e.g., high-dose bicalutamide)
Beskrivning

antiandrogen

Datatyp

boolean

Alias
UMLS CUI [1]
C0002842
no prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), pc-spes, or estrogen-containing nutraceuticals
Beskrivning

5-alpha reductase inhibitors, pc-spes, or estrogen-containing nutraceuticals

Datatyp

boolean

Alias
UMLS CUI [1]
C2936788
UMLS CUI [2]
C0756934
UMLS CUI [3]
C0014939
no concurrent systemic steroid therapy (topical steroids allowed)
Beskrivning

systemic steroids

Datatyp

boolean

Alias
UMLS CUI [1]
C2825233
Tillbaka till toppen

Similar models

Eligibility Prostate Cancer NCT00379119

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
adenocarcinoma of the prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Radical prostatectomy
Item
underwent prior radical prostatectomy as local definitive therapy for prostate cancer
boolean
C0194810 (UMLS CUI [1])
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade)
Item
has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery
boolean
C1518041 (UMLS CUI [1])
C3495882 (UMLS CUI [2])
rising prostate-specific antigen; no objective evidence of metastatic disease
Item
serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease
boolean
C0201544 (UMLS CUI [1])
C0027627 (UMLS CUI [2])
Radiotherapy
Item
prior radiotherapy for serologic progression allowed
boolean
C1522449 (UMLS CUI [1])
androgen blockade therapy
Item
did not receive any form of androgen blockade therapy within the past 9 months
boolean
C0279492 (UMLS CUI [1])
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
Item
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
boolean
C0027627 (UMLS CUI [1,1])
C0203669 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C1641132 (UMLS CUI [2,2])
Item Group
Inclusion Criteria: Patient Characteristics
C0815172 (UMLS CUI-1)
CT scan
Item
able to tolerate ct scanning in the supine position
boolean
C0040405 (UMLS CUI [1])
medical condition affecting the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
Item
no prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
boolean
C0012634 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0040113 (UMLS CUI [1,3])
C0026896 (UMLS CUI [2])
C0024299 (UMLS CUI [3])
C0020550 (UMLS CUI [4])
C0006625 (UMLS CUI [5])
autoimmune disorders
Item
no autoimmune disorders
boolean
C0004364 (UMLS CUI [1])
no acute illness, including active infection
Item
no acute illness, including active infection requiring antibiotics
boolean
C0001314 (UMLS CUI [1])
C0009450 (UMLS CUI [2])
concurrent therapy
Item
prior concurrent therapy: see disease characteristics
boolean
C0009429 (UMLS CUI [1])
systemic chemotherapy
Item
no prior systemic chemotherapy
boolean
C1883256 (UMLS CUI [1])
immunological therapy
Item
no prior immunological therapy
boolean
C0021083 (UMLS CUI [1])
antiandrogen
Item
no prior single-agent antiandrogen (e.g., high-dose bicalutamide)
boolean
C0002842 (UMLS CUI [1])
5-alpha reductase inhibitors, pc-spes, or estrogen-containing nutraceuticals
Item
no prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), pc-spes, or estrogen-containing nutraceuticals
boolean
C2936788 (UMLS CUI [1])
C0756934 (UMLS CUI [2])
C0014939 (UMLS CUI [3])
systemic steroids
Item
no concurrent systemic steroid therapy (topical steroids allowed)
boolean
C2825233 (UMLS CUI [1])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial